Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.

Pinelli NR, Jantz A, Smith Z, Abouhassan A, Ayar C, Jaber NA, Clarke AW, Commissaris RL, Jaber LA

Journal of clinical pharmacology19 May 2010Cited by 15 (Europe PMC)

PMID20484613DOI10.1177/0091270010367653PepBankPUB-20484613

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, exenatide reduced caloric intake versus placebo.
In plain wordsIn healthy volunteers, exenatide reduced calorie intake compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCaloric intake
Study
n = 20
Comparator
placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
Compared with placebo, exenatide reduced caloric intake (P = .0059), food intake (P = .0032), and glucose concentrations at 60 (P < .001) and 120 minutes after meals (P = .015).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461301
02HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, exenatide reduced food intake versus placebo.
In plain wordsIn healthy volunteers, exenatide reduced food intake compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake
Study
n = 20
Comparator
placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
Compared with placebo, exenatide reduced caloric intake (P = .0059), food intake (P = .0032), and glucose concentrations at 60 (P < .001) and 120 minutes after meals (P = .015).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461302
03HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, exenatide reduced glucose at 60 minutes after meals versus placebo.
In plain wordsIn healthy volunteers, exenatide reduced blood sugar 60 minutes after meals compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose at 60 minutes
Study
n = 20
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
Compared with placebo, exenatide reduced caloric intake (P = .0059), food intake (P = .0032), and glucose concentrations at 60 (P < .001) and 120 minutes after meals (P = .015).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461303
04HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, exenatide reduced glucose at 120 minutes after meals versus placebo.
In plain wordsIn healthy volunteers, exenatide reduced blood sugar 120 minutes after meals compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose at 120 minutes
Study
n = 20
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
Compared with placebo, exenatide reduced caloric intake (P = .0059), food intake (P = .0032), and glucose concentrations at 60 (P < .001) and 120 minutes after meals (P = .015).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461304
05HumanRandomized controlled trialSafety outcome
In healthy volunteers, nausea was more frequent with exenatide than placebo.
In plain wordsIn healthy volunteers, exenatide caused more nausea than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n = 20
Comparator
placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 µg · single doseAs given in this study (human).
Measurements
Nausea
63%
exenatide
Nausea
20%
placebo
Source sentences
Summary
Nausea (63% vs 20%), reduced appetite (43% vs 10%), and vomiting (18% vs 0%) occurred more frequently in exenatide-treated subjects compared with placebo (P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461305
06HumanRandomized controlled trialSafety outcome
In healthy volunteers, reduced appetite was more frequent with exenatide than placebo.
In plain wordsIn healthy volunteers, reduced appetite occurred more often with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseReduced appetite adverse event
Study
n = 20
Comparator
placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Measurements
Reduced appetite
43%
exenatide
Reduced appetite
10%
placebo
Source sentences
Summary
Nausea (63% vs 20%), reduced appetite (43% vs 10%), and vomiting (18% vs 0%) occurred more frequently in exenatide-treated subjects compared with placebo (P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461306
07HumanRandomized controlled trialSafety outcome
In healthy volunteers, vomiting was more frequent with exenatide than placebo.
In plain wordsIn healthy volunteers, vomiting occurred more often with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseVomiting
Study
n = 20
Comparator
placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 µg · single doseAs given in this study (human).
Measurements
Vomiting
18%
exenatide
Vomiting
0%
placebo
Source sentences
Summary
Nausea (63% vs 20%), reduced appetite (43% vs 10%), and vomiting (18% vs 0%) occurred more frequently in exenatide-treated subjects compared with placebo (P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461307
08HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, exenatide given further from meals reduced caloric intake more than dosing closer to meals.
In plain wordsIn healthy volunteers, exenatide given further from meals reduced calorie intake more than dosing closer to meals.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCaloric intake by administration timing
Study
n = 20
Comparator
exenatide closer to meals
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
Significant differences were noted in caloric intake (P = .0149) and food intake (P = .0205) based on the administration time of exenatide, with doses given further from meals producing reduced feeding responses.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461308
09HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, exenatide given further from meals reduced food intake more than dosing closer to meals.
In plain wordsIn healthy volunteers, exenatide given further from meals reduced food intake more than dosing closer to meals.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake by administration timing
Study
n = 20
Comparator
exenatide closer to meals
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
Significant differences were noted in caloric intake (P = .0149) and food intake (P = .0205) based on the administration time of exenatide, with doses given further from meals producing reduced feeding responses.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461309
10HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, postprandial glucose did not differ by exenatide administration timing.
In plain wordsIn healthy volunteers, blood sugar after meals did not differ between exenatide administration times.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePostprandial glucose by administration timing
Study
n = 20
Comparator
other exenatide administration times
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
No such difference was found in postprandial glucose concentrations or adverse events based on timing of exenatide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461310
11HumanRandomized controlled trialSafety outcome
In healthy volunteers, adverse events did not differ by exenatide administration timing.
In plain wordsIn healthy volunteers, adverse events did not differ between exenatide administration times.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse events by administration timing
Study
n = 20
Comparator
other exenatide administration times
Outcome group
Adverse events · Whole body
Studied dose
10 µg · single doseAs given in this study (human).
Source sentences
Summary
No such difference was found in postprandial glucose concentrations or adverse events based on timing of exenatide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative…
Report a problemFND-2048461311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.